| abstract |
The present invention provides 19-nor-D-homoesteroids, which has an androgenic / progestagen profile, which are orally active, prevent loss of trabecular bone mineral density (BMD), and which lacks hepatic toxicity, which has an agreeable structure. with formula I: (see formula (I)) in which R1 is O, or NOR, where R is hydrogen, alkyl with 1 to 6 carbon atoms or acyl with 1 to 6 carbon atoms, R2 is methyl or ethyl, and R3 is hydrogen or acyl with 1 to 15 carbon atoms. |